Novartis Kisqali gains early breast cancer indication

Kannan D/iStock Editorial via Getty Images The U.S. FDA has granted an additional indication for Novartis' ( NYSE: NVS ) Kisqali (ribociclib) to treat earlier stages of breast cancer.

The selective cyclin-dependent kinase inhibitor, in combination with an aromatase inhibitor, is now approved as an adjuvant treatment for HR+/HER2- stage II and III.